[Autologous bone marrow transplantation for acute leukemia].
Autologous bone marrow transplantation (ABMT) was performed in 20 common ALL antigen (CALLA) positive acute lymphoblastic leukemia (ALL) cases. Bone marrow cells harvested in complete remission (CR) were in vitro treated with monoclonal antibodies NL-1 (IgG2a: anti-CD10), NL-22 (IgM), HL-47 (IgM) and baby rabbit complement and cryo-preserved. Three children with high risk factor such as Ph1 chromosome were transplanted in 1st CR, 5 in 2-3 CR, 8 adults in 1st CR, 2 in 2nd CR and 2 in relapse. As conditioning of ABMT, 12 cases mostly in 1st CR were treated with 4 doses of 2 g/m2 cytarabine (CA), 2 doses of 60 mg/kg cyclophosphamide (CY) and 4 doses of 3 Gy total body irradiation (TBI). 6 cases refractory to CA/CY were treated with 3 doses of 60 mg/m2 melphalan and 4 doses of 3 Gy TBI. Disease free survival (DFS) of 11 cases in 1st CR was 81.8% at 2 years from ABMT, and 9 cases are alive in CR. DFS of 5 cases in 2nd CR was 40.0%. In one Ph1 chromosome positive case, minimal residual bcr-abl mRNA was detected by polymerase chain reaction in the 1st CR bone marrow, but disappeared after purging procedures and after 3 months from ABMT. Our results indicate that ABMT with purged bone marrow is an effective mode of therapy for high risk CALLA positive ALL.
Kataoka
T
T
First Department of Internal Medicine, Nagoya University School of Medicine.
Miyamura
K
K
D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000401:mortality / Q000601:surgery*; D015996:Survival Rate; D014182:Transplantation, Autologous